source
- Opinion: Are blue zones real? Answering that question is harder than ever"Blue zones" as a concept have strayed far and wide from their humble roots, write Shelley Wood and Eric Topol.STAT · 3mo ago↗ source
- Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companiesChina is now a peer competitor in drug innovation — and it intends to stay that way on its own terms, writes Dennis Kwok.STAT · 3mo ago↗ source
- UCB bets $2B on Candid's T cell engager ambitionsKen Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is…Endpoints · 3mo ago